Telisotuzumab Vedotin clinical trials
3 indexed studies · 1 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2, Open-Label Study in Subjects with Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new medicine, Telisotuzumab Vedotin, for people with a specific type of lung cancer that hasn't been treated before. Researchers want to see how well it shrinks tumours and helps patients feel better. It's an important step in finding new treatments.
For: Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerRomania · Germany · Italy - Active not recruitingPHASE2
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
This study is testing a new medicine called telisotuzumab vedotin for people with a specific type of advanced non-small cell lung cancer where a protein called c-Met is present. It aims to find out who benefits most and how well it works.
For: Non-small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
For: Non Small Cell Lung CancerUnited States · Argentina · Australia